by Sermonix Pharmaceuticals | Jun 3, 2019 | News
Sermonix-sponsored University of Chicago preclinical investigation demonstrated: Lasofoxifene alone was significantly more effective than fulvestrant at inhibiting metastasis of both MCF7-Y537S and D538G tumors to the lungs and liver.Lasofoxifene, in combination with...
by Sermonix Pharmaceuticals | Jun 2, 2019 | News
CHICAGO—Findings suggest that lasofoxifene, in combination with CDK4/6 inhibitors like palbociclib, is a promising approach for the treatment of endocrine therapy resistant ER+ metastatic breast cancer patients (Abstract 1056). “Lasofoxifene is a legacy molecule...
Recent Comments